Table 5.

Fold decrease in neutralization compared to Prototype/D614 G or other variant, with live virus or pseudovirus neutralization assay.

Neutralization assay	Vaccination program	Number of vaccine doses	Alpha Vs. Prototype/D614 G	Beta Vs. Prototype/D614 G	Delta Vs. Prototypen/D614 G	Omicron Vs. Prototype/D614 G	Omicron Vs. Delta
Pseudovirus neutralization assay	Total	2	↓×1.19–1.65	↓×2.83–16.32	↓×1.37–6.97	↓×11.16–109.87	↓×5.81–21.5
		3	↓×0.66–1.42	↓×0.86–8.97	↓×0.75–9.23	↓×2.2–15.97	↓×0.77–15.66
	Inactivated vaccine booster group	2	↓×1.65	↓×7.62–13.65	↓×1.92–3.17	↓×11.16–68.25	↓×5.81–21.5
		3	↓ 1.3	↓ 1.32–2.2	↓×1.14–1.7	↓×5.1–5.86	↓×3.05–5.15
	mRNA vaccine booster group	2	↓×1.19	↓×2.83–16.32	↓×1.37–6.97	↓×18.38–109.87	↓×10.43–17.44
		3	↓×1.42	↓×1.3–8.97	↓×0.89–9.23	↓×2.2–15.97	↓×0.77–11.79
	Recombinant protein subunit vaccine booster group	3	↓×0.66–0.8	↓×0.86–1.8	↓×0.75–1	↓×3.1–10.6	↓×4.13–10.16
	Mixed vaccine booster group (different types of vaccines)	3	/	↓×1.63–1.82	↓×0.96–1.45	↓×2.47–14.98	↓×1.71–15.66
Live virus neutralization assay	Total	2	/	↓×1.07–13.04	↓×1–7.2	↓×1.59–104.89	↓×1.59–14.84
		3	/	↓×1–15	↓×0.76–7.5	↓×2.9–26.87	↓×2.47–13.9
	Inactivated vaccine booster group	2	/	↓×1.26	↓×1–5.1	↓×1.59–16.0	↓×1.59–3.14
		3	/	↓×1.85	↓×1.72–3.3	↓×5.88–16.5	↓×3.43–5.05
	mRNA vaccine booster group	2	/	↓×1.07–13.04	↓×1.52–7.2	↓×4–104.89	↓×2.64–14.84
		3	/	↓×1.3-15	↓×1.5–7.5	↓×4–26.87	↓×2.67–6.67
	Viral vector vaccine booster group	2	/	/	↓×5.20	↓×18.57	↓×3.57
		3	/	/	↓×1.2–3.51	↓×2.9–12.7	↓×2.47–3.6
	Recombinant protein subunit vaccine booster group	3	/	/	/	/	/
	Mixed vaccine booster group (different types of vaccines)	3	/	↓×1–2.37	↓×0.76–2.1	↓×6.7–10.6	↓×6.72–13.9